Inhibitor Therapeutics Flags Going Concern, $3M Default Judgment, and FDA Path Forward
INTI has more than doubled off its 52-week low of $0.034.
Summary
Inhibitor Therapeutics' Q2 2026 filing reveals a going concern warning with only $515,758 in cash, a $3.0 million default judgment against an investor, and an FDA Type C meeting scheduled for written responses by end of September 2026.
Key Events · Earnings and Guidance · INTI
-
Going Concern Warning
Cash and cash equivalents fell to $515,758 as of June 30, 2026, from $2,375,493 at December 31, 2025. Management projects insufficient liquidity to sustain operations through one year, raising substantial doubt about the company's ability to continue as a going concern.
-
$3M Default Judgment
On August 3, 2026, the Delaware Court of Chancery awarded a default judgment of $3.0 million plus attorney's fees and interest against an institutional investor that failed to fund a securities purchase agreement. Collection is uncertain and no receivable has been recorded.
-
FDA Type C Meeting
The FDA granted a Type C meeting request on July 23, 2026, and will provide written responses by the end of September 2026 regarding the proposed surgically eligible endpoint for itraconazole in BCCNS. A negative response could require additional clinical trials the company cannot fund.
-
Provisional Patent Filed
On August 14, 2026, the company filed a provisional U.S. patent application covering a novel oral itraconazole formulation developed with Avior Bio, potentially extending protection beyond the 2029 expiration of the licensed JHU patent.
Analysis · INTI · Life Sciences
With cash down to $515,758, the company has issued a going concern warning. A $3.0 million default judgment against an institutional investor could provide relief, though collection remains uncertain. Meanwhile, the FDA has granted a Type C meeting with written responses expected by the end of September 2026—a critical milestone for the itraconazole program.
At the time of this filing, INTI was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $14.1M. The 52-week trading range was $0.03 to $0.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.